Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.
Shares of Myriad Genetics closed at $29.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Myriad Genetics (MYGN) Announces Upcoming Presentations of Strong myPath Melanoma Data
- Piper Jaffray Downgrades Quintiles (Q) to Neutral
- Deutsche Bank Downgrades Allegheny Technologies (ATI) to Hold
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesWells Fargo
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!